Results 121 to 130 of about 10,636 (238)

To test or not to test: what we have learnt from 50 years of dynamic testing in acromegaly. [PDF]

open access: yesPituitary
De Marinis L   +7 more
europepmc   +1 more source

Safety of 12‐Months Administration of Ashwagandha ( Withania somnifera ) Standardized Root Extract in Healthy Adults: A Prospective, Observational Study

open access: yesPhytotherapy Research, Volume 40, Issue 8, Page 4802-4812, August 2026.
ABSTRACT Ashwagandha, an adaptogen, is an important herb of Ayurveda used as a Rasayana for its various health benefits. This prospective, multi‐center, observational clinical study evaluates the safety (clinical and laboratory) of a standardized Ashwagandha Root Extract (ARE) on long‐term administration over 12 months. Male and female adults (N = 191)
Jaising Salve   +6 more
wiley   +1 more source

Evaluation of Potential Hormonal Activities of Ashwagandha (Withania somnifera)

open access: yesPhytotherapy Research, Volume 40, Issue 8, Page 4880-4897, August 2026.
ABSTRACT Ashwagandha is a widely used herb in traditional medicine systems, particularly Ayurveda. Despite its extensive tradition, growing concerns regarding its potential endocrinological effects have prompted scientific scrutiny. This review systematically evaluates the current preclinical, clinical, and case study evidence concerning AS's effects ...
Günter Vollmer, Thomas Brendler
wiley   +1 more source

Safety Evaluation of an Aqueous Root and Leaf Extract of Ashwagandha ( Withania somnifera )

open access: yesPhytotherapy Research, Volume 40, Issue 8, Page 5030-5047, August 2026.
Sensoril, an aqueous root and leaf extract of ashwagandha showed no evidence of mutagenicity in the in vitro Ames assay, was negative in the in vitro micronucleus, in vivo mammalian bone marrow chromosome aberration assays, and was well tolerated in the rat at up to 4000 mg/kg BW/day when administered orally for a period of 90 days. The data from these
Mukesh Summan   +2 more
wiley   +1 more source

Towards a Safe and Effective Lithium Therapeutic Range for Older Adults With Bipolar Disorder: An ISBD Task Force Systematic Review

open access: yesBipolar Disorders, Volume 28, Issue 5, August 2026.
ABSTRACT Objectives Lithium is recommended as the first‐line maintenance treatment for older adults with bipolar disorder (OABD). However, age‐related reduction in renal clearance, heightened sensitivity to adverse effects, and drug interactions increase the risk of toxicity and necessitate lower therapeutic serum levels in this population.
Paula V. Nunes   +15 more
wiley   +1 more source

Concurrent Hashimoto's Encephalopathy and Papillary Thyroid Carcinoma: A Case Report

open access: yesClinical and Experimental Neuroimmunology, Volume 17, Issue 3, August 2026.
ABSTRACT Background Hashimoto's encephalopathy (HE) is a rare steroid‐responsive autoimmune syndrome. Although HE is associated with anti‐thyroid antibodies, its concurrence with malignant thyroid tumors has rarely been described and its clinical implications remain poorly understood.
Ryo Hara   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy